Alteration in the CD4+ T cell pool was most probably related to the development of the malignant condition itself since prostate cancer patients had a mildly reduced CD4+ T cell pool which was not significantly influenced by LDR brachytherapy. The gene discussed is CD4; the disease is prostate carcinoma.